Browsing Over 15 Sessions
Session Type
  • Industry Satellite Symposium
 Filtered By

Sort By
View

Roche - Precision oncology in Asia: A new dawn or a false hope? (ID 61)

Time
12:45 PM - 02:15 PM

AstraZeneca - PARP inhibitors as targeted therapy for personalised medicine (ID 58)

Time
12:45 PM - 02:15 PM

MSD - A quantum leap in treatment of NSCLC and HNSCC with IO (ID 62)

Time
12:45 PM - 02:15 PM

Pfizer - From clinical trials to practice: Changing the trajectory for metastatic breast cancer patients (ID 60)

Time
12:45 PM - 02:15 PM

AstraZeneca - Changing the course for the lung cancer patient: A new direction (ID 57)

Time
12:45 PM - 02:15 PM

Novartis - Evolving treatment landscape in ER+ breast cancer: Clinical practice (ID 66)

Time
12:45 PM - 02:15 PM

Pfizer - Treating EGFR+ NSCLC in 2020: New approaches, optimal outcomes (ID 64)

Time
12:45 PM - 02:15 PM

Merck Pfizer Alliance - Recent advances and future possibilities with immunotherapy in renal and urothelial cancers (ID 67)

Time
12:45 PM - 02:15 PM

MSD - Advances in immune-oncology: A Pan tumour perspective (ID 65)

Time
12:45 PM - 02:15 PM

AstraZeneca - Evolving the treatment practice of advanced EGFRm NSCLC (ID 63)

Time
12:45 PM - 02:15 PM

Ipsen - Managing HCC today: How can we give our patients the best chance? (ID 68)

Time
12:45 PM - 02:15 PM

Takeda - Redefining ALK+ NSCLC management (ID 71)

Time
11:00 AM - 12:30 PM